Inclusion Criteria:

- Measurable or evaluable disease(evaluable according to CA125 criteria of GCIG)
Cisplatin resistant ovarian cancer

- Persistent or progression to first line platinum-based chemotherapy

- Relapse within 6 months after completing first line platinum-based chemotherapy

- Platinum-sensitive disease who are failed to second line therapy based on platinum.

- Adequate organic function as defined by: hemoglobin >10 g/L, leukocytes >4000/mm3,
platelets >100 000mm3; normal creatinine value and creatinine clearance >60 mL/min;
total bilirubin < 1.5 upper normal limit value

Exclusion Criteria:

- History of allergy to hydralazine or valproate;

- Past or present condition of rheumatic disease, central nervous system disease, heart
failure from aortic stenosis and postural hypotension as diagnosed by a physician;

- Newly diagnosed hypertension patients with or without pharmacological treatment are
allowed as long as their treatment do not include hydralazine.

- Previous use of the experimental drugs (hydralazine and magnesium valproate) as well
as if patients were pregnant or breast-feeding.

Other exclusion criteria are uncontrolled systemic disease or infection.